Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)

To evaluate activity and toxicity of a non platinum-based triplet including Gemcitabine, Ifosfamide and Navelbine (GIN) in advanced NSCLC. Stage IIIB/IV NSCLC patients with WHO PS < 2 and bidimensionally measurable disease entered the study. Gemcitabine 1000 mg/sqm day 1 and 1000–800 mg/sqm day 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldini, E, Ardizzoni, A, Prochilo, T, Cafferata, M A, Boni, L, Tibaldi, C, Neumaier, C, Conte, P F, Rosso, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363940/
https://www.ncbi.nlm.nih.gov/pubmed/11720427
http://dx.doi.org/10.1054/bjoc.2001.2108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363940/
https://www.ncbi.nlm.nih.gov/pubmed/11720427
http://dx.doi.org/10.1054/bjoc.2001.2108

Ejemplares similares